Develop autoimmune disease treatments
coultreon.comLinkedInLeuven, BelgiumBiotechFounded 2025
5 sources
Galapagos is identified as an earlier seed investor and is also named as a participant in this Series A, so it is included in this round's syndicate.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $125M | 2026-04-28 | Forbion, Novo Holdings, Sofinnova Partners | No recent discussion |
5 sources [ VERIFIED · CORRECTED ] read against 1 of 5 sources
Galapagos is identified as an earlier seed investor and is also named as a participant in this Series A, so it is included in this round's syndicate. | ||||
Checked against 8 sources on Oct 5